Trametinib -- a new drug for Melanoma


Trametinib is a new drug developed by GSK plc to treat Melanoma. It is a MEK inhibitor. In 2013, it was approved by the US FDA for marketing. As a single drug oral tablet, MEKINIST is suitable for carrying BRAF V600E or V600K mutations